Request Demo
Last update 19 Apr 2025
Pembrolizumab/Quavonlimab
Last update 19 Apr 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms quavonlimab/pembro, MK 1308A, MK-1308A |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 93660H
The sequence is quoted from: *****
Sequence Code 93670L
The sequence is quoted from: *****
Sequence Code 432609798H
The sequence is quoted from: *****
Sequence Code 432609800L
The sequence is quoted from: *****
Related
10
Clinical Trials associated with Pembrolizumab/QuavonlimabCTR20220530
在晚期肾透明细胞癌（ccRCC）患者中开展的一项开放标签、随机III期研究，旨在评估帕博利珠单抗（MK-3475）联合Belzutifan（MK-6482）及仑伐替尼（MK-7902），或MK-1308A联合仑伐替尼，相比于帕博利珠单抗联合仑伐替尼作为一线治疗的有效性和安全性
[Translation] An open-label, randomized, phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) plus Belzutifan (MK-6482) and lenvatinib (MK-7902), or MK-1308A plus lenvatinib, compared with pembrolizumab plus lenvatinib as first-line treatment in patients with advanced clear cell renal cell carcinoma (ccRCC)
CTR20211819
一项在晚期肝细胞癌受试者中评价MK-1308A（MK-1308/MK-3475复方）联合仑伐替尼（E7080/MK-7902）用于一线治疗的安全性和有效性的II期、多中心临床研究
[Translation] A phase II, multicenter clinical study evaluating the safety and efficacy of MK-1308A (MK-1308/MK-3475 combination) combined with lenvatinib (E7080/MK-7902) as first-line treatment in subjects with advanced hepatocellular carcinoma
CTR20211132
在晚期实体瘤受试者中开展的MK-1308联合帕博利珠单抗的I / II期、开放性、多组、多中心研究
[Translation] A Phase I/II, Open-label, Multi-Group, Multi-Center Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
100 Clinical Results associated with Pembrolizumab/Quavonlimab
Login to view more data
100 Translational Medicine associated with Pembrolizumab/Quavonlimab
Login to view more data
100 Patents (Medical) associated with Pembrolizumab/Quavonlimab
Login to view more data
100 Deals associated with Pembrolizumab/Quavonlimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | China | 27 Jul 2022 | |
| Renal Cell Carcinoma | Phase 3 | United States | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | China | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | Japan | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | Australia | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | Brazil | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | Canada | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | Chile | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | Colombia | 14 Apr 2021 | |
| Renal Cell Carcinoma | Phase 3 | Croatia | 14 Apr 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free